摘要
腹膜癌是癌症治疗历史上遗留的“老大难”问题,近40年来国际上致力于腹膜癌诊断治疗研究,取得了突破性进展,尤其是肿瘤细胞减灭术(cytoreductive surgery,CRS)加腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC)体系的形成和优化。近20年来,中国的腹膜癌研究进步迅速,在仪器设备研发、技术方案优化、人才队伍培养、学科组织建设等方面,均取得令人瞩目的成就,并快速融入腹膜肿瘤学国际联盟的国际化发展大格局。中国胃癌腹膜转移癌临床研究成果成为国际里程碑事件,C-HIPEC方案的推广实施,2021年国内主办第12届国际腹膜癌大会,都是该领域的突出成果,也使中国在腹膜癌诊治方面实现了从跟跑并跑到领跑的历史性转变。但是,与中国腹膜癌患者的巨大治疗需求相比,腹膜肿瘤学发展事业仍然任重而道远,需要全国肿瘤学家加倍努力,推动立足于国情的中国腹膜癌防治研究走向新高度。
The treatment of peritoneal metastasis(PM) has been a long-standing significant challenge in clinical oncology. In the past two decades, considerable progress has been made in the diagnosis and treatment of PM, due to concerted research efforts in the field. This is characterized by the development and refinement of cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC).In this time, China has achieved remarkable success in PM prevention and treatment, particularly by developing new treatment methods,optimizing new technologies, cultivating groups of experts who specialize in PM, establishing nationwide academic organizations, and collaborating with international organizations such as the Peritoneal Surface Oncology Group International(PSOGI). Examples of landmark progress in China include a series of clinical studies on PM associated with gastric cancer, which have been internationally adopted as reference data;the adoption and promotion of the China-HIPEC(C-HIPEC) concept;and hosting the 12th International Congress on Peritoneal Surface Malignancies in 2021. These historical achievements have contributed to China becoming one of the international leaders in the development of treatments for PM. However, because of the large number of patients requiring effective CRS and HIPEC, the prevention and treatment of PM in China requires further development. Nationwide concerted efforts among clinical oncologists should be emphasized for further advancement in this crucial area of clinical oncology.
作者
李雁
朱正纲
崔书中
梁寒
王辉
蔡国响
许洪斌
彭正
党诚学
武爱文
杨盈赤
杨智冉(翻译)
Yan Li;Zhenggang Zhu;Shuzhong Cui;Han Liang;Hui Wang;Guoxiang Cai;Hongbin Xu;Zheng Peng;Chengxue Dang;Aiwen Wu;Yingchi Yang(Department of Peritoneal Cancer Surgery,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China;Department of General Surgery,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China;Department of Gastrointestinal Surgery,Affiliated Cancer Hospital and Institute of Guangzhou Medical University,Guangzhou 510095,China;De-partment of Gastric Oncology Surgery,Tianjin Medical University Cancer Institute&Hospital,Tianjin 300060,China;Department of Colorectal and Anal Surgery,The Sixth Affiliated Hospital Sun Yat-sen University,Guangzhou 510655,China;Department of Large In-testine,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Myxoma,Aerospace Center Hospital,Beijing 100049,China;Department of General Surgery,The First Medical Center of the PLA General Hospital,Beijing 100853,China;Department of Oncological Surgery,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China;Gastrointestinal Oncology Center,Peking University Cancer Hospital,Beijing 100143,China;Department of General Surgery,Beijing Friendship Hos-pital,Capital Medical University,Beijing 100050,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2022年第24期1256-1262,共7页
Chinese Journal of Clinical Oncology
关键词
腹膜癌
肿瘤细胞减灭术
腹腔热灌注化疗
发展
peritoneal carcinoma
cytoreductive surgery(CRS)
hyperthermic intraperitoneal chemotherapy(HIPEC)
development